ReviewVaccines2022
Toward a Multivalent Synthetic Oligosaccharide-Based Conjugate Vaccine against
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Oligosaccharide adjuvant-deferred antigen endocytosis promotes cross-presentation.Bioactive materials · 2027Article
- Review
- Preclinical evaluation of multivalent vaccine combinations againstFrontiers in immunology · 2026Article
- An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs.The American journal of tropical medicine and hygiene · 2025Article
- Article
- TestingPharmaceutics · 2024Article
- Optimizing Vaccine Trials for Enteric Diseases: The Enterics for Global Health (EFGH)Open forum infectious diseases · 2024Article
- Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.The Lancet. Global health · 2023Review
- Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target.Microbiology and molecular biology reviews : MMBR · 2023Review
- Development of themSphere · 2023Article
- Article
- Characterization of Shigella flexneri Serotype 6 Strains Isolated from Bangladesh and Identification of a New Phylogenetic Cluster.Journal of bacteriology · 2023Article
- Etiology, Presentation, and Risk Factors for Diarrheal Syndromes in 3 Sub-Saharan African Countries After the Introduction of Rotavirus Vaccines From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults.NPJ vaccines · 2023Article
- Toward aInternational journal of molecular sciences · 2023Review
- The Diversity ofMicroorganisms · 2023Review
- Comparison ofFrontiers in molecular biosciences · 2023Article
- Impact and Control of Sugar Size in Glycoconjugate Vaccines.Molecules (Basel, Switzerland) · 2022Review
- Frontiers inVaccines · 2022Article
- TheVaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
This review focuses on the molecular glycovaccine concept, a promising option to develop a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.